Fauci’s Deadly Blind Spot: Steroids Worked

Fauci’s Deadly Blind Spot: Steroids Worked

From Rand Radio by Rand Paul Review

March 25, 2026 · 1 min

About this episode

Senator Rand Paul discusses the overlooked potential of steroids in treating severe COVID-19 cases and criticizes Dr. Fauci's dismissal of this treatment option.

Senator Rand Paul just slammed the last nail in the coffin of the low-cost solution that could have possibly saved thousands of Americans. The slow-burning anger that rises within you whenever you add another piece of the COVID puzzle together and you begin to realize just how badly they messed with you. Senator Rand Paul recently recapped his first attempt (early, urgent) to get Anthony Fauci to consider using High-Dose Intravenous Steroids for those patients who were seriously ill (severe inflammation/crashing lungs). Steroids had proven effective against similar storms in other illnesses. Senator Paul explained this clearly; Dr. Fauci dismissed it flatly, “No.” Then Dr. Fauci went back to touting Remdesivir as the golden ticket. A drug that barely improved survival rates for the patients, and at an enormous cost to the patients’ kidneys, and their bank accounts. The data did not need permission. The RECOVERY trial provided some irrefutable numbers that nobody could spin: Dexamethasone reduced death rates in ventilated patients by approximately 1/3. From approximately 41% down to 29%. That is not statistics; that is people breathing again, leaving hospitals, returning to their…

People in this episode

Host: Rand Paul

Topics covered

  • COVID-19 treatment
  • health policy
  • medical ethics
  • pharmaceuticals
  • government response

Keywords

  • COVID-19
  • steroids
  • Dexamethasone
  • Remdesivir
  • Anthony Fauci
  • Rand Paul
  • RECOVERY trial
  • healthcare
  • treatment options

Mentioned in this episode

Organizations: NIH

Products: High-Dose Intravenous Steroids, Remdesivir, Dexamethasone

More episodes of Rand Radio

Explore listener stats, chart rankings, contacts and more on the Rand Radio podcast page.